AIM ImmunoTech (AIM) Stock Price, News & Analysis

Company Overview

AIM ImmunoTech Inc. is a biotechnology company focused on developing and commercializing immune-based therapies for cancer, chronic disorders and infectious diseases. The company’s lead product candidate is Ampligen (rintatolimod), an investigational double-stranded RNA immunomodulator designed to stimulate components of the immune system. Ampligen has been studied in conditions including myalgic encephalomyelitis/chronic fatigue syndrome, certain cancers and viral infections, although it is not broadly approved by the U.S. Food and Drug Administration.

AIM also markets Alferon N Injection, a formulation of natural human alpha interferon. The product has U.S. approval for the treatment of certain refractory or recurring external genital and perianal warts caused by human papillomavirus. The company has conducted research and pursued development activities involving its immune-modulating technologies in the United States and through international collaborations and regulatory efforts.

The company was formerly known as Hemispherx Biopharma Inc. and adopted the name AIM ImmunoTech Inc. in 2019. Its corporate offices are in Ocala, Florida. Thomas K. Equels has served as the company’s chief executive officer and has been involved in directing its development and commercialization strategy.

Key Stats

• Today's Range: $0.15 to $0.15
• 50-Day Range: $0.14 to $0.23
• 52-Week Range: $0.12 to $1.88
• Volume: 69,156 shs
• Average Volume: 10.60 million shs
• Market Capitalization: $4.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

AIM ImmunoTech Stock Analysis - MarketRank™

AIM ImmunoTech scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AIM ImmunoTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

AIM ImmunoTech has a consensus price target of $9.00, representing about 5,900.0% upside from its current price of $0.15.

Amount of Analyst Coverage

AIM ImmunoTech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AIM ImmunoTech are expected to grow in the coming year, from ($0.78) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AIM ImmunoTech is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AIM ImmunoTech is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.32% of the float of AIM ImmunoTech has been sold short.

Short Interest Ratio / Days to Cover

AIM ImmunoTech has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AIM ImmunoTech has recently decreased by 7.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AIM ImmunoTech does not currently pay a dividend.

Dividend Growth

AIM ImmunoTech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 7 news articles for AIM ImmunoTech this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $42,522.00 in company stock, which represents 0.9313% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, AIM ImmunoTech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,522.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.82% of the stock of AIM ImmunoTech is held by insiders.

Percentage Held by Institutions

12.02% of the stock of AIM ImmunoTech is held by institutions.

Company Calendar

• Last Earnings: 11/12/2026
• Today: 11/13/2026
• AGM 2026: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:AIM
• Previous Symbol: NYSEAMERICAN:HEB
• CIK: 946644
• Web: aimimmuno.com
• Phone: (352) 448-7797
• Fax: 215-988-1739
• Employees: 21
• Year Founded: 1990

Price Target and Rating

• Average Price Target for AIM ImmunoTech: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +5,900.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($24.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.96 million
• Net Margins: -15,021.05%
• Pretax Margin: -15,021.05%
• Return on Equity: N/A
• Return on Assets: -143.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 50.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.99) per share
• Price / Book: -0.05

Miscellaneous

• Outstanding Shares: 30,440,000
• Free Float: 30,192,000
• Market Cap: $4.57 million
• Optionable: Not Optionable
• Beta: 1.32